Expert Rev Neurother. 2025 Mar 25. doi: 10.1080/14737175.2025.2484439. Online ahead of print.
ABSTRACT
INTRODUCTION: Cenobamate (CNB) is an anti-seizure medication (ASM)utilized for drug-resistant focal-onset seizures, which are difficult to managewith usual agents. Previous studies demonstrated that it can be effective inpatients with refractory epilepsy.
METHODS: The MEDLINE, Cochrane, and Scopus databases weresystematically searched up to 24 October 2024. A Random-effects model wasemployed to compute the Mean Difference (MD) and the Risk Ratio (RR) with 95%Confidence Intervals (CI). Statistical Analyses were performed utilizingRStudio 4.4.2.
RESULTS: Four studies were included, comprising 906 patients; 527(59%) received CNB as add-on therapy. The results indicated that the 50%responder rate (RR 1.77; 95% CI: 1.28 to 2.44, p = 0.000551, I² = 70.3%) andseizure freedom (RR of 3.09; 95% CI: 1.91 to 5.00, p = 0.000004, I² = 8.7%)were significantly higher in this group.
CONCLUSIONS: In this meta-analysis of four studies, CNB as an add-ontherapy significantly reduced seizure frequency in patients with uncontrolledfocal seizures, making it a promising option for improved seizure control andquality of life.
PMID:40131227 | DOI:10.1080/14737175.2025.2484439
